Adverse effects of the angiotensin-converting enzyme inhibitors

Annals of Pharmacotherapy

Volumn 30, Issue 1, 1996, Pages 55-61

  Alderman, Christopher P ^a,b  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; ARTICLE; COUGHING; DYSGEUSIA; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; LIVER TOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK MANAGEMENT; TERATOGENESIS;

EID: 0030029187     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000110     Document Type: Article

References (64)

1. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 1991;17: 589-92.
2. Salvetti A. Newer ACE inhibitors. A look at the future. Drugs 1990;40: 800-28.
3. Garrison JC, Peach MJ. Cardiovascular drugs. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1991:757-62.
4. Opie LH. Angiotensin convening enzyme inhibitors. Scientific basis for clinical use. New York: John Wiley and Sons, 1992:2
5. Whitworth JA, Clarkson D, Dwyer T, Glaszious P, Jackson T, Komer P, et al. The management of hypertension: a consensus statement. Med J Aust 1994;160(suppl):S1-S16.
6. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
8. DiBianco R. A large-scale trial of captopril for mild to moderate heart failure in the primary care setting. Clin Cardiol 1991;14:676-82.
9. Cohn JN, Johnson G, Ziesche S, Cobh F, Francis G, Tnstani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.
10. Vannan MA, Taylor DJE, Webb-Peploe MW, Konstam MA, ACE inhibitors after myocardial infarction may benefit patients with left ventricular dysfunction. BMJ 1993;306:531-2.
11. Sutton M. Should angiotensin converting enzyme (ACE) inhibitors be used routinely after infarction? Perspectives from the Survival and Ventricular Enlargement (SAVE) trial. Br Heart J 1994;71:115-8.
12. Cody RJ. Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction Arch Intern Med 1994;154:2029-36.
13. Mogensen CK. Renoprotective role of ACE inhibitors in diabetic nephropathy. Br Heart J 1994;72(Suppl):S38-S45.
14. ter Wee PM, Epstein M. Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease. Arch Intern Med 1993;153:1749-59
15. Warner NJ, Rush JE. Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs 1988;35(suppl 5):89-97.
16. Dabaghi S. ACE inhibitors and pancreatitis (letter). Ann Intern Med 1991;115:330-1.
17. Enalapril. Peripheral neuropathy (letter). Clin Alert 1993;1993:19.
18. Savino LB, Haushalter NM, Lisinopril-induced "scalded mouth syndrome." Ann Pharmacother 1992,26:1381-2.
19. Gynaecomastia induced by angiotensin converting enzyme inhibitor (letter). BMJ 1990;300:541.
20. Femer RE. Adverse effects of angiotensin-converting-enzyme inhibitors. Adv Drug React Bull 1990;141:528-31.
21. Warner NJ, Rush JE. Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs 1988,35(suppl 5):89-97.
22. Oster JR, Materson BJ. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med 1992;152 704-10.
23. Reid JL, MacFadyen RJ, Squire IB. Lees KR. Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose Am Heart J 1993;126:794-7.
24. Webster J. Angiotensin converting enzyme inhibitors in the clinic: first-dose hypotension J Hypertens 1994;5:527-530.
25. Parish RC, Miller LJ Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Saf 1992;7:14-31.
26. ACE inhibitor first dose effect (editorial). Med J Aust 1993;158:208
27. Elliott HL. Antihypertensive drugs. In: Dukes MNG, ed. Meyler's side effects of drugs. Amsterdam: Elsevier Science, 1992.478-90.
28. Maxwell SRJ, Kendall MJ. ACE inhibition in the 1990s. Br J Clin Pharmacol 1993;47:30-7.
29. Drugs used in the treatment of diseases of the cardiovascular system. In. Prasad AB, ed. British national formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1993:87.
30. Cleland JGF, Dargie HJ, McAlpine H, Ball SG, Morton JJ, Robertson JIS, et al. Severe hypotension after first dose of enalapril in heart failure. Br Med J 1985;291:1309-12.
31. Macdonald G. Angiotensin-converting enzyme inhibitors. Med J Aust 1994;160:279-81.
32. Speirs CJ, Dollery CT, Inman WHW, Wilton LV. Postmarketing surveillance of enalapril. II: investigation of the potential role of enalapril in deaths with renal failure. Br Med J 1988;297:830-2.
33. Mason NA Angiotensin-converting enzyme inhibitors and renal function. Ann Pharmacother 1990;24:496-505.
34. Munger MA. Renal functional alterations induced by angiotensin-converting enzyme inhibitors in heart failure. Ann Pharmacother 1993;27:205-10.
35. Materson BJ, Preston RA. Angiotensin-converting enzyme inhibitors in hypertension. Arch Intern Med 1994;154:513-23.
36. Gavras I, Gavras H. The use of ACE inhibitors in hypertension. In: Kostts JB, DeFelice EA, eds. Angiotensin converting enzyme inhibitors. New York. Alan R Liss, 1987:93-122.
37. Cough caused by ACE inhibitors. Drug Ther Bull 1994;32:28.
38. Lefebvre J, Poirier L, Lacourcière Y. Prospective trial on captopril-related cough. Ann Pharmacother 1992:26:161-4.
39. Sharif MN, Evans BL, Pylypchuk GB. Cough induced by quinapril with resolution after changing to fosinopril. Ann Pharmacother 1994,28:720-2.
40. Strocchi E, Malini PL, Valtancoli G, Ricci C, Bassein L, Ambrosiani E. Cough during treatment with angiotensin converting enzyme inhibitors. Analysis of predisposing factors. Drug Invest 1992;4:69-72.
41. Inman WHW, Wilton L, Pearce G, Mann RD. Angiotensin converting enzyme inhibitors and asthma (letter). BMJ 1994;308:593-4.
42. Lunde H, Hedner T, Samuelsson O, Lotvall J, Andren L, Lindholm L, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994;308:18-21.
43. Hargreaves MR, Benson MK. Inhaled sodium cromoglycate in angiotensin-converting enzyme cough. Lancet 1995;345:13-6.
44. Navis GJ, deJong PE, Kallenberg CGM, DeMonchy J, deZeeuw D. Absence of cross-reactivity between captopril and enalapril (letter). Lancet 1984;1:1017.
45. Rotmensch HH, Vlasses PH, Ferguson RK. Resolution of captopril-induced rash after substitution of enalapril. Pharmacotherapy 1983;3:131-3.
46. Kubo SH, Cody RJ. Enalapril, a rash, and captopril (letter). Ann Intern Med 1984;100:616.
47. Zazgornik J, Kaiser W, Biesenbach G. Captopril-induced dysgeusia (letter). Lancet 1993;341:1542.
48. Drugs that leave a bad taste in the mouth. Adv Drug React Bull 1992;11:14.
49. Captopril product information. Cardiovascular system - antihypertensive agents. In: Badewitz-Dodd LH, Tuckwell KR. eds. MIMS Annual 1993. Crows Nest, NSW: Wills CR - MediMedia Australia Proprietary Limited. 1993:41-3.
50. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-23.
51. Breckenridge A. Angiotensin converting enzyme inhibitors. Br Med J 1988;296:618-20.
52. Johnston CI, Arnolda L, Hiwatari M Angiotensin converting enzyme inhibitors in the treatment of hypertension. Drugs 1984;27:271-7.
53. Hagley MT, Hulisz DT, Burns CM. Hepatotoxicity associated with an giotensin-converting enzyme inhibitors. Ann Pharmacother 1993;27:228-31.
54. Valle R, Carrascosa M, Cillero L, Perez-Castrillon JL. Enalapril-induced hepatotoxicity (letter). Ann Pharmacother 1993;27:1405.
55. Hagley MT, Benak RL, Hulisz DT. Suspected cross-reactivity of enalapril- and captopril-induced hepatotoxtcity. Ann Pharmacother 1992;26:780-1.
56. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD. Inman WHW, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988;260:967-70
57. Hanssens M, Keirse MJNC, Vankelecom F, Van Assche AF. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991;78:128-35
58. Brown NJ, Nadeau JH. Does race predispose to angiotensm-associated angioneurotic edema (letter)? Ann Intern Med 1993;119:1224.
59. Chan WK, Chan TY, Luk WK, Leung VK, Li TH, Critchley JA. A high incidence of cough in Chinese subjects treated with angiotensin convening enzyme inhibitors. Eur J Clin Pharmacol 1993;44:299-300.
60. Brent RL, Beckman DA. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical teratology counsellors. Teratology 1991;43:543-6.
61. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994;96:451-6.
62. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol 1992;80:429-32.
63. Barr M, Cohen MM ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. Obstet Gynecol Surv 1992:393-5.
64. Thorpe-Beston JG, Armar NA, Dancy M, Cochrane GW, Ryan G, Rodeck CH, et al. Pregnancy and ACE inhibitors. Br J Obstet Gynaecol 1993;100:692-3